Keep your SARS-CoV-2 testing workflows running at full speed

Reagents for testing and public health labs

One of the many challenges of the public health response to COVID-19 is ensuring that labs have enough high-quality reagents for uninterrupted SARS-CoV-2 testing. With our immense oligonucleotide synthesis capacity and robust reagent supply chain, LGC Biosearch Technologies™ can remove reagent bottlenecks and keep your SARS-CoV-2 testing workflows running at full speed.

It's not you, it's your oligo. Read how to mitigate the risk of oligo contamination to preserve the integrity of your COVID-19 workflow.

Developing your own kit? What do you require to develop your SARS-CoV-2 assay?Let us know how we can help.

Secure your supply chain needs for scalable SARS-CoV-2 detection

We have mobilised all necessary resources to support global testing requirements. From nucleic acid extraction and purification to critical assay components such as enzymes, master mix, probes and primers, we enable you to respond to COVID-19 rapidly and at scale.

Play video
Why choose Biosearch Technologies to support your COVID-19 detection programs?

Easily order probes and primers by protocol, including CDC-published probe sequences

Run your tests with the confidence of knowing that the powerful BHQ™ and BBQ-650™ dyes used in many of the SARS-CoV-2 protocols are coming straight from the company that is the original supplier and inventor

Leverage sensitive and robust qPCR enzymes and master mixes from the trusted partner of the world’s top 10 molecular diagnostic firms

All COVID-19 orders will be prioritised and expedited for detection at scale

Consult our team for tools and technologies for SARS-CoV-2

“Biosearch Beats the Deadline - Yet another partner went above and beyond: Biosearch Technologies in Novato, in Northern California, produces the Black Hole Quencher dye label used for probe technology in both the five target and H1N1 assays. It increased production at the onset of the pandemic to meet US and international demand for test reagents.”

 
Excerpt from page 80 of “Lessons from a virus: Public Health Laboratories Respond to the H1N1 Pandemic” Association for Public Health Laboratories
Recorded Q&A panel discussion: How to establish COVID-19 diagnostics and keep up with demand

Three leading experts discuss the experiences and challenges they faced when developing, validating and going live with a SARS CoV-2 assay in routine diagnostics as well as the challenges of ramping up test volumes to meet demand while maintaining quality standards. In addition, products specifically designed for SARS-CoV-2 testing, assay validation and QC that can support continued diagnostics at high volumes will be discussed by LGC experts.

View recording

Need some technical support on your protocol?

Ask a scientist
Products to support your workflow

Automation-compatible products for high-quality RNA extraction and purification from a range of clinical samples, including upper respiratory specimens.

High-performance reverse transcriptase (RT) options that can fit into a range of workflows.

We enable sensitive pathogen detection with our trusted master mix reagents.

We offer ready-to-use probe and primer sets that enable confident and scalable SARS-CoV-2 testing.

We safeguard the integrity of your COVID-19 workflows by manufacturing and shipping oligos in a completely separate and geographically distant facility from positive control production.

We’re the inventor and original source of all the quenching technologies that are cited in the protocols published by WHO

You can rely on our secure, vertically integrated supply chain which allows us to manufacture oligos quickly and at scale

Move quickly with a ready-to-use, out-of-the-box solution for high complexity CLIA labs running the CDC EUA protocol. 

Pick and choose which COVID-19 signatures work best for your lab with individual RUO probes and primers using sequences as designated by Charité and US CDC protocols:

Request probes of your own design using the BHQ technology we invented:

LGC Clinical Diagnostics (formerly SeraCare) offers a complete Quality Solution for COVID-19 diagnostic assay validation

AccuPlex™ technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient. These materials serve as true, full-process quality solutions that challenge the entire diagnostic workflow, making them the preferred alternative to infectious materials.

Together, the AccuPlex SARS-CoV-2 Verification Panel and AccuPlex SARS-CoV-2 Reference Material Kit offer an ideal solution for clinical laboratories looking for a safe, effective tool to verify and monitor SARS-CoV-2 molecular assay performance. Products contain positive materials directed against the published CDC and WHO consensus sequences and the S gene. Negative materials targeting the human RNase P gene are also included.

LEARN MORE

“We just went ‘live’ with the SARS-CoV-2 assay…I’ve never brought in and validated an assay in 7 days. The LGC SeraCare reference material works perfectly. I needed something other than the assay’s positive control to create a positive assay result before I felt comfortable releasing the assay for patient testing, and your product did the trick.”

Medical Director, Clinical Chemistry Laboratory prominent Boston Academic Medical Hospital

 

Working with you to wield science for a safer world.